Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy

Clinical Cancer Research

Volumn 11, Issue 2 I, 2005, Pages 814-825

  Sharma, Surinder K ^a   Pedley, R Barbara ^a   Bhatia, Jeetendra ^a   Boxer, Geoffrey M ^a   El Emir, Ethaar ^a   Qureshi, Uzma ^a   Tolner, Berend ^a   Lowe, Helen ^a   Michael, N Paul ^b   Minton, Nigel ^c   Begent, Richard H J ^a   Chester, Kerry A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISIODOPHENOL; CARCINOEMBRYONIC ANTIGEN; HEXAHISTIDINE; HISTIDINE DERIVATIVE; HYBRID PROTEIN; PHENOL DERIVATIVE; PRODRUG; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; ZD 2767 P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CANCER INHIBITION; CANCER MODEL; CHEMICAL REACTION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ASSAY; ENZYME LOCALIZATION; ENZYME SPECIFICITY; FEMALE; GENE FUSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MANNOSYLATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PICHIA PASTORIS; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PURIFICATION; TISSUE DISTRIBUTION; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; FEMALE; GAMMA-GLUTAMYL HYDROLASE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MANNOSE; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; NITROGEN MUSTARD COMPOUNDS; PICHIA; PRODRUGS; PROTEIN ENGINEERING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 19944427731     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Bagshawe KD, Sharma SK, Springer C J, et al. Antibody directed enzyme prodrug therapy (ADEPT): clinical report. Dis Markers 1991; 9:233-8.
2. Bagshawe KD, Sharma SK, Springer CJ, Antoniw P. Antibody-directed enzyme prodrug therapy: a pilot scale clinical trial. Tumour Targeting 1995;1:17-29.
3. Napier MP, Sharma SK, Springer CJ, et al. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 2000;6:765-72.
4. Bagshawe KD, Springer CJ, Searle F, et al. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 1988;58:700-3.
5. Senter PD, Saulnier MG, Schreiber GJ, et al. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci U S A 1988;85:4842-6.
6. Retta BME, Burke PJ, Photiou A, Melton RG, EnoAmooquaye E. Antibody-directed enzyme prodrug therapy (ADEPT): evidence for a bystander effect in vitro. Int J Oncol 1996;9:567-70.
7. Cheng TL, Wei SL, Chen BM, et al. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug. Br J Cancer 1999;79:1378-85.
8. Bagshawe KD. Antibody directed enzymes revive anti-cancer prodrugs concept. Br J Cancer 1987;56:531-2.
9. Senter PD, Springer CJ. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev 2001;53: 247-64.
10. Francis RJ, Sharma SK, Springer CJ, et al. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer 2002;87:600-7.
11. Michael NP, Chester KA, Melton RG, et al. In vitro and in vivo characterisation of a recombinant carboxypeptidase G(2)::anti-CEA scFv fusion protein. Immunotechnology 1996;2:47-57.
12. Bhatia J, Sharma SK, Chester KA, et al. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. Int J Cancer 2000;85:571-7.
13. Medzihradszky KF, Spencer DI, Sharma SK, et al. Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein. Glycobiology 2004;14:27-37.
14. Springer CJ, Dowell R, Burke PJ, et al. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem 1995;38:5051-65.
15. Casey JL, Keep PA, Chester KA, Robson L, Hawkins RE, Begent RHJ. Purification of bacterially expressed single-chain Fv antibodies for clinical-applications using metal chelate chromatography. J Immunol Methods 1995;179:105-16.
16. Mayer A, Chester KA, Bhatia J, et al. Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: preparation of a genetically engineered anti-CEA single chain Fv antibody. Eur J Cancer 1998;34:968-76.
17. Sherwood RF, Melton RG, Alwan SM, Hughes P. Purification and properties of carboxypeptidase G2 from Pseudomonas sp strain Rs-16: use of a novel triazine dye affinity method. Eur J Biochem 1985;148: 447-53.
18. Blakey DC, Burke PJ, Davies DH, et al. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts. Cancer Res 1996; 56:3287-92.
19. Mayer A, Tsiompanou E, Flynn AA, et al. Higher dose and dose-rate in smaller tumors result in improved tumor control. Cancer Invest 2003; 21:382-8.
20. Pedley RB, Boden JA, Boden R, et al. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agent. Cancer Res 1996;56:3293-300.
21. Bretthauer RK, Castellino FJ. Glycosylation of Pichia pastoris-derived proteins. Biotechnol Appl Biochem 1999;30:193-200.
22. Pratap J, Rajamohan G, Dikshit KL. Characteristics of glycosylated streptokinase secreted from Pichia postons: enhanced resistance of SK to proteolysis by glycosylation. Appl Microbiol Biotechnol 2000;53: 469-75.
23. Moorman F, Barret-Bergshoeff MM, Rijken DC. Role of carbohydrate and protein in the binding of tissue-type plasminogen activator to the human mannose receptor. Eur J Biochem 1998;251:107-13.
24. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001;46:149-68.
25. Yuan F, Baxter LT, Jain RK. Pharmacokinetic Analysis of 2-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res 1991;51:3119-30.
26. Sharma SK, Bagshawe KD, Burke PJ, Boden RW, Rogers GT. Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. Br J Cancer 1990;61:659-62.
27. Sharma SK, Bagshawe KD, Springer CJ, et al. Antibody directed enzyme prodrug therapy (ADEPT): a three phase system. Dis Markers 1991;9:225-31.
28. Kerr DE, Garrigues US, Wallace PM, Hellstrom KE, Hellstrom I, Senter PD. Application of monoclonal antibodies against cytosine deamirtase for the in vivo clearance of a cytosine deaminase immunoconjugate. Bioconjug Chem 1993;4:353-7.
29. Haisma HJ, Van Muijen M, Scheffer G, Scheper RJ, Pinedo HM, Boven E. A monoclonal antibody against human p-glucuronidase for application in antibody-directed enzyme prodrug therapy. Hybridoma 1995;14:377-82.
30. Cheng TL, Chen BM, Chern JW, Wu MF, Roffler SR. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug Chem 2000;11:258-66.
31. Melton RG. Preparation and purification of antibody-enzyme conjugates for therapeutic applications. Adv Drug Deliv Rev 1996;22: 289-301.
32. Rose K, Vilaseca LA, Werlen R, et al. Preparation of well-defined protein conjugates using enzyme: assisted reverse proteolysis. Bioconjug Chem 1991;2:154-9.
33. Werlen RC, Lankinen M, Rose K, et al. Site-specific conjugation of an enzyme and an antibody fragment. Bioconjug Chem 1994;5:411-7.
34. Siemers NO, Kerr DE, Yarnold S, et al. Construction, expression, and activities of L49-sFv-β-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation. Bioconjug Chem 1997;8:510-9.
35. Bosslet K, Czech J, Hoffmann D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res 1994; 54:2151-9.
36. Monks NR, Blakey DC, Curtin NJ, East SJ, Heuze A, Newell DR. Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue. Br J Cancer 2001;85:764-71.
37. Webley SD, Francis RJ, Pedley RB, et al. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material. Br J Cancer 2001;84:1671-6.
38. Pedley RB, Hill SA, Boxer GM, et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Res 2001;61:4716-22.
39. Sharma SK. Immune response in ADEPT. Adv Drug Deliv Rev 1996;22:369-76.
40. Bagshawe KD, Sharma SK. Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT. Transplant Proc 1996;28:3156-8.
41. Chen BM, Cheng TL, Tzou SC, Roffler SR. Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy. Int J Cancer 2001;94:850-8.
42. Begent RHJ, Verhaar MJ, Chester KA, et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 1996;2:979-84.
43. Spencer DIR, Robson L, Purdy D, et al. A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. Proteomics 2002;2:271-9.
44. Bagshawe KD. The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites. Br J Cancer 1989; 60:275-81.
45. Sharma SK, Boden JA, Springer CJ, Burke PJ, Bagshawe KD. Antibody-directed enzyme prodrug therapy (ADEPT): a three-phase study in ovarian tumor xenografts. Cell Biochem Biophys 1994; 24-25:219-28.
46. Eccles SA, Court WJ, Box GA, Dean CJ, Melton RG, Springer CJ. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2. Cancer Res 1994;54: 5171-7.
47. Pedley RB, Sharma SK, Boxer GM, et al. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res 1999;59:3998-4003.